ClinicalTrials.gg
Not yet recruitingNCT07863713Updated Oct 7, 2026

Early Intervention for High Risk Premyopic Children

A Phase 2 interventional study of 0.025% atropine eye drops and DIMS TED in Myopia, sponsored by National Yang Ming Chiao Tung University Hospital. Not yet recruiting. Open to participants aged 5 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by National Yang Ming Chiao Tung University Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
5 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Planned enrollment
15th of 54
240 · median 144
Started
2026
with 5 others
Phase 2
7 of 54
3 open now
Primary completion
2033-10
later than 23 of 23 live
Registered
54th of 54
by date
Lead sponsor
2 of 54
National Yang Ming Chiao Tung University Hospital

Among the 54 studies testing atropine in Myopia, this one is the 15th largest by planned enrollment, is one of 6 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 23 of the 23 other live ones, and was the 54th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 5 Years to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

The purpose of this research project is to add evidence of pharmacological (0.025% atropine) and optical (Defocus Integrated Multiple Segments Triple Enhanced Design spectacle lenses ) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention strategy for myopia control in premyopic children.

Read the detailed description

With the increasing popularity of screen-based digital devices in the post-pandemic era, childhood myopia prevention and control has become a growing global challenge. Although the protective effect of increased outdoor time has been well established, the optimal strategy for preventing or delaying the onset of childhood myopia remains to be determined, particularly among pre-myopic children around the age of school entry. A substantial increase in myopia prevalence has been reported before and after entry into elementary school, and children with early-onset myopia are at increased risk of rapid progression and subsequent development of high myopia later in life.

Recent evidence suggests that low-concentration atropine eye drops may reduce the incidence of childhood myopia. However, photophobia and other dose-related adverse effects associated with higher concentrations of atropine may interfere with daytime visual activities and potentially reduce children's willingness to engage in outdoor activities. In addition, evidence regarding optical interventions for the prevention of myopia onset remains limited.

These unmet clinical needs motivate us to propose a randomized controlled trial evaluating optical and pharmacological approaches for myopia prevention using Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED) spectacle lenses and 0.025% atropine eye drops, respectively, in pre-myopic preschool children aged 5-6 years.

In this proposed study, we plan to recruit a total of 240 eligible participants identified as pre-myopic and asymptomatic through a population-based eye care program in Yilan County. Eligible participants will be randomly assigned to three groups: the DIMS TED spectacle lens group (n=80), the 0.025% atropine group (n=80), and the usual-care group (n=80).

Because environmental and near-work demands are generally lower during preschool than after entry into elementary school, children assigned to the DIMS TED group will be instructed to wear the spectacles using a stepwise strategy: primarily at home and during near-work activities during the preschool stage, followed by full-time wear after entering elementary school.

Cycloplegic spherical equivalent (SE) refraction and axial length will be measured every 6 months during the 7-year follow-up period. The primary outcome will be the change in mean cycloplegic SE over the study period among the three groups. Secondary outcomes will include the cumulative incidence of myopia, the cumulative proportion of participants exhibiting a fast myopic shift in SE, and changes in mean axial length over the study period.

This proposed project may provide further evidence regarding early optical and pharmacological intervention strategies for myopia prevention and may support the development of an eye-care model emphasizing early identification and intervention for pre-myopic preschool children before or around the time of elementary school entry.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • myopia
  • DIMS TED
  • Atropine
  • Outdoor activities
04

Who can participate

Ages eligible
5 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at enrollment: 5-6 years old (the senior grade of kindergarten)
  • Cycloplegic SE of the eye with less SE (less positive or more negative refractive error): \< +1.00 D and > -0.50 D
  • Astigmatism: 1.5 D or less in both eyes
  • Anisometropia: 1.50 D or less
  • Monocular uncorrected visual acuity: 6/7.5 or better in both eyes
  • Either of the parents with moderate myopia
  • Acceptance of random group allocation
  • Submission of complete .

Exclusion criteria

Exclusion Criteria:

  • Strabismus or any ocular motility disorder
  • Any ophthalmic and systemic disorders that might affect visual functions or refractive development
  • Previous treatment of atropine or other myopia control intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    DIMS TED

    Stepwise wearing of DIMS TED

    Device: DIMS TED

  • Active comparator
    0.025% Atropine

    Daily administration of 0.025% Atropine

    Drug: 0.025% atropine eye drops

  • No intervention
    Normal activities

    Normal promotion of outdoor activities

Interventions

  • DrugAtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daily instillation of 0.025% atropine

  • DeviceDIMS TED

    Stepwise wearing of DIMS TED

06

What researchers measure

Primary outcomes

  1. Myopic shift of spherical equivalent refraction

    The change of mean cycloplegic spherical equivalent refraction over 7 years

    Time frame: 7 years

Secondary outcomes

  1. Axial length elongation

    The change of mean axial length over 7 years

    Time frame: 7 years

  2. Incidence of myopia

    the cumulative percentage of incident myopia

    Time frame: 7 years

  3. Fast myopic shift of spherical equivalent refraction

    the cumulative percentage of fast myopic shift of spherical equivalent refraction

    Time frame: 7 years

  4. Subfoveal choroidal thickness

    the vertical distance from the outer edge of the retinal pigment epithelium (or Bruch's membrane) to the inner surface of the sclera (the chorioscleral border) directly beneath the fovea

    Time frame: 7 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2033, 84 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Oct 24, 2026
Primary completionEst.
Oct 24, 2033
CompletionEst.
Oct 24, 2033
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863713
Lead sponsor
National Yang Ming Chiao Tung University Hospital
Responsible party
Der-Chong Tsai, MD PhD (Principal Investigator, National Yang Ming Chiao Tung University Hospital) — Principal investigator
First posted
Oct 7, 2026
Start date
Oct 24, 2026 (estimated)
Primary completion
Oct 24, 2033 (estimated)
Completion
Oct 24, 2033 (estimated)
Last update
Oct 7, 2026

Study contacts

Hsin-Yu Yang MD, MD
Contact
lisa771102@yahoo.com.tw
+886 3 9325192
Hsin-Yu Yang
principal investigator · National Yang Ming Chiao Tung University Hospital, Yilan, Taiw

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion